BeiGene, Ltd. (BGNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
BGNE POWR Grades
- Value is the dimension where BGNE ranks best; there it ranks ahead of 69.72% of US stocks.
- The strongest trend for BGNE is in Momentum, which has been heading down over the past 52 weeks.
- BGNE's current lowest rank is in the Momentum metric (where it is better than 4.19% of US stocks).
BGNE Stock Summary
- BGNE's price/sales ratio is 31.07; that's higher than the P/S ratio of 92.93% of US stocks.
- With a year-over-year growth in debt of 187.01%, BeiGene Ltd's debt growth rate surpasses 94.64% of about US stocks.
- Revenue growth over the past 12 months for BeiGene Ltd comes in at 299.9%, a number that bests 97.35% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to BeiGene Ltd, a group of peers worth examining would be ALNY, SGEN, QRVO, STM, and WDC.
- Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.
BGNE Valuation Summary
- In comparison to the median Healthcare stock, BGNE's EV/EBIT ratio is 171.33% lower, now standing at -20.9.
- BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.
- BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.
Below are key valuation metrics over time for BGNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BGNE | 2021-08-31 | 30.3 | 8.0 | -21.9 | -20.9 |
| BGNE | 2021-08-30 | 29.7 | 7.8 | -21.4 | -20.5 |
| BGNE | 2021-08-27 | 27.7 | 7.3 | -20.0 | -19.1 |
| BGNE | 2021-08-26 | 27.8 | 7.3 | -20.1 | -19.1 |
| BGNE | 2021-08-25 | 28.5 | 7.5 | -20.6 | -19.6 |
| BGNE | 2021-08-24 | 28.1 | 7.4 | -20.3 | -19.3 |
BGNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
- BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
- AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.
The table below shows BGNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.168 | 0.883 | -0.377 |
| 2021-03-31 | 0.165 | 0.897 | -0.358 |
| 2020-12-31 | 0.065 | 0.771 | -0.552 |
| 2020-09-30 | 0.070 | 0.746 | -0.678 |
| 2020-06-30 | 0.078 | 0.704 | -0.890 |
| 2020-03-31 | 0.166 | 0.826 | -0.893 |
BGNE Stock Price Chart Interactive Chart >
BGNE Price/Volume Stats
| Current price | $347.69 | 52-week high | $426.56 |
| Prev. close | $351.51 | 52-week low | $219.20 |
| Day low | $340.00 | Volume | 125,200 |
| Day high | $353.99 | Avg. volume | 265,929 |
| 50-day MA | $367.80 | Dividend yield | N/A |
| 200-day MA | $336.18 | Market Cap | 32.47B |
BeiGene, Ltd. (BGNE) Company Bio
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.
Latest BGNE News From Around the Web
Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
BeiGene''s Brukinsa Approved In Europe For Rare Type Of Blood CancerThe European Commission has approved BeiGene Ltd''s (NASDAQ: BGNE ) BRUKINSA (zanubrutinib) for Waldenström''s macroglobulinemia (WM). WM is a type of non-Hodgkin lymphoma. This rare blood cell cancer is characterized by an excess of abnormal white blood cells in the bone marrow. The approval covers adult WM patients who Full story available on Benzinga.com |
3,062 Shares in BeiGene, Ltd. (NASDAQ:BGNE) Acquired by California State Teachers Retirement SystemCalifornia State Teachers Retirement System acquired a new position in BeiGene, Ltd. (NASDAQ:BGNE) during the second quarter, HoldingsChannel.com reports. The fund acquired 3,062 shares of the companys stock, valued at approximately $1,051,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Parallel Advisors LLC boosted its holdings in [] |
10 Best China Stocks to Buy NowIn this article, we will discuss the 10 best China stocks to buy now. You can skip our detailed analysis of China’s stock market, and go directly to read the 5 Best China Stocks to Buy Now. According to a report published by Wall Street Journal, China’s key benchmark, MSCI China Index, gained 27% in […] |
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenströms MacroglobulinemiaBASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces approval of BRUKINSA (zanubrutinib) in the European Union for treatment of adults with Waldenströms macroglobulinemia. |
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström''s MacroglobulinemiaEU approval follows recent approvals for BRUKINSAincluding U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (N |
BGNE Price Returns
| 1-mo | -2.80% |
| 3-mo | 15.20% |
| 6-mo | -5.26% |
| 1-year | 21.62% |
| 3-year | 141.60% |
| 5-year | 1,000.63% |
| YTD | 34.56% |
| 2020 | 55.88% |
| 2019 | 18.18% |
| 2018 | 43.53% |
| 2017 | 221.87% |
| 2016 | N/A |
Continue Researching BGNE
Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...